Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Mallinckrodt's Stannsoporfin Gets Complete Response Letter
by Zacks Equity Research
Mallinckrodt's (MNK) pipeline candidate, Stannsoporfin gets a Complete Response Letter from the FDA.
Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio
by Kinjel Shah
The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.
Alnylam Completes Enrollment in Phase III Givosiran Study
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.
Infinity Focuses on Developing IPI-549 for Solid Tumors
by Zacks Equity Research
Infinity Pharmaceuticals (INFI) aims at developing its pipeline candidate, IPI-549.
Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC
by Zacks Equity Research
AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.
Is Celgene Set to See Improved Results in the Second Half?
by Zacks Equity Research
After a series of pipeline setbacks, things are looking better for biotech bigwig Celgene (CELG) with positive data read-outs and an increase in guidance.
Novo Nordisk Buys Ziylo to Develop Glucose Responsive Insulin
by Zacks Equity Research
Novo Nordisk A/S (NVO) acquires Ziylo Ltd. to speed up the development of glucose responsive insulins in a deal that could exceed $800 million.
Top 5 ROE Picks on Optimism Over Resolution of Trade Dispute
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
Geron's Growth Depends on Continuation of Imetelstat Studies
by Zacks Equity Research
Investors continue to focus on development of Geron's (GERN) sole pipeline candidate, imetelstat. However, competition is rife with other companies developing treatments for similar indications.
Turkey Drives Up Worry: Global Week Ahead
by John Blank
The Turkish Lira rout that started last week is the big story for this coming week. In turn, U.S. and European earnings seasons are winding down.
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech
by Zacks Equity Research
Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.
Corcept (CORT) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
The Zacks Analyst Blog Highlights: Caterpillar, BHP Billiton and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caterpillar, BHP Billiton and Celgene
Quiet in August: Global Week Ahead
by John Blank
We are now in a quiet period for the equity markets. August is where many traders take vacations, and daily volume is relatively light.
Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?
by Zacks Equity Research
Prothena's (PRTA) Q2 results are likely to reflect pipeline updates along with progress with its restructuring plan.
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.
Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Agios (AGIO) incurs narrower-than-expected loss in Q2. Additionally, higher license and collaboration/milestone fees lead to a significant year-over-year rise in revenues.
Regeneron Pharmaceuticals (REGN) Jumps: Stock Rises 7%
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Zacks.com featured highlights include: Celgene, Progressive, T. Rowe Price, AMC and Celanese
by Zacks Equity Research
Zacks.com featured highlights include: Celgene, Progressive, T. Rowe Price, AMC and Celanese
Top 5 ROE Picks as Q2 Earnings Shine Despite Trade War Woes
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
The Zacks Analyst Blog Highlights: Celgene, Exxon Mobil, Berkshire Hathaway, Phillips 66 and VMware
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Exxon Mobil, Berkshire Hathaway, Phillips 66 and VMware
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Top Stock Reports for Celgene, Exxon Mobil & Berkshire Hathaway
by Mark Vickery
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Exxon Mobil (XOM) and Berkshire Hathaway (BRK.B).
What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?
by Zacks Equity Research
On Agios' (AGIO) second-quarter 2018 conference call, investor focus is likely to be on the launch preparations of the company's newly FDA approved leukemia drug, Tibsovo.